E therapies. Due to high inter- and intra-patient tumor heterogeneity, identification
E therapies. Due to high inter- and intra-patient tumor heterogeneity, identification of molecular lesions driving myeloma in individual sufferers is essential for the improvement of novel therapeutic algorithms . Apart…